Skip to main content

Find a clinical trial

AMC303-01

A safety, tolerability and pharmacokinetic dose escalation expansion, Phase I/Ib study of AMC303 as monotherapy in patients with advanced or metastatic, malignant solid tumour of epithelial origin Philippe Aftimos

(FIERCE-22)

A Multi-Center, Single-Arm, Open-Label Phase 1b Study of a Novel FGFR3 Inhibitor (B-701) Combined with Pembrolizumab in Subjects with Locally Advanced or Metastatic Urothelial Carcinoma who have Progressed Following Platinum-based Chemotherapy Philippe Aftimos

IJB_2691

Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse Spyridon Sideris

1367.1

An open label, Phase Ia/Ib dose finding study with BI 894999 orally administeredonce a day in patients with advanced malignancies, with repeated administration in patients with clinical benefit Ahmad Hussein Awada

METASUN UCL-ONCO 2012-09

A proof of concept study to evaluate the use of metabonomics and lipidomics in predicting toxicity and efficacy of anti-VEGF therapy in patients with metastatic clear cell renal cell carcinoma Thierry Gil

CLEAR

A Multicenter, Open-Label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma (CLEAR) Spyridon Sideris

EORTC 1658

Qualification of imaging methods to assess cancer drug induced interstitial lung disease (ImageILD) Konstantinos Stathopoulos

GO29674

A phase Ib, open-label, dose-escalation study of the safety and Pharmacokinetics of MOXR0916 and MPDL3280A in patients with locally advanced or metastatic solid tumors Ahmad Hussein Awada

OX2016-203-01

An open-label, dose-escalation, phase I study to assess the safety, pharmacokinetics and pharmacodynamics of AsiDNA, a DNA repair inhibitor administered intravenously in patients with advanced solid tumors Nuria Kotecki

WO29636

WO29636 A Phase III, Open-Label, Multicenter, Randomized Study Of Atezolizumab (Anti-PD-L1 Antibody) Versus Observation As Adjuvant Therapy In Patients With High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection. Spyridon Sideris

CL1-81694-001

Phase I dose-escalation study of S 81694 administered intravenously in adult patients with advanced/metastatic solid tumours Ahmad Hussein Awada

SYD985.001

A two part first-in-human phase I study (with expanded cohorts) with the antibody-drug conjugate SYD985 to evaluate the safety, pharmacokinetics and efficacy in patients with locally advanced or metastatic solid tumors Philippe Aftimos

T2001-01

An Observational Study to Collect Data Characterizing Analgesia in Patients Suffering From Bone Metastasis Induced Pain. Dominique Lossignol

STORM

PEACE V: A randomized phase II trial for the Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM)

Intervention dyadique

Reinforcement of onco-psychological interventions by the development of psychological support for patients and their significant others

AURA

Avelumab as neoadjuvant therapy in subjects with urothelial muscle invasive bladder cancers Thierry Gil

Sevrage Tabagique

Impact of an emotion and craving regulation intervention on smoking cessation and maintenance among oncology patients : a randomised study Darius Razavi

Intervention destinée aux parents

Children facing parental cancer : a randomized controlled study evaluating the efficacy of a psychological intervention to support parenting Darius Razavi

A-48-52030-269 IMIO

An International, Multicentric, prospective, open LaBEL study to assess the efficacy and safety of Lanreotide Autogel 120 mg associated to standard of care in the treatment of clinical symptoms associated with inoperable malignant intestinal obstruction (IMIO) Dominique Lossignol